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The cerium Ce(III), lanthanum La(III), and neodymium Nd(III) complexes with 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-
benzopyran-2-one (warfarin) (W) and 3,3 -benzylidenebis[4-hydroxycoumarin] (1) were synthesized and studied for the ﬁrst
time for cytotoxicity (on MT-2 cells) and as anti-HIV agents under acute and chronic infection. The complexes were characterized
by diﬀerent physicochemical methods: mass spectrometry, 1H NMR, 13C NMR, and IR spectroscopy. The spectra of the complexes
were interpreted on the basis of comparison with the spectrum of the free ligands. Anti-HIV eﬀect of the complexes/ligands was
measured in MT-2 cells by microtiter infection assay. Detection of endogenous reverse transcriptase (RT) activity and RT pro-
cessivity by PCR indicative for proviral DNA synthesis demonstrated that anti-HIV activity has not been linked to early stages of
viralreplication.Noeﬀect on late steps of viral replication has been found using cells chronically producing HIV-1LAI virus. La(W)
demonstrated anti-HIV activity (IC50=21.4μM) close to maximal nontoxic concentration. Nd(W), Ce(1), and Nd(1)d e m o n -
strated limited anti-HIV potency, so none of the complexes seems appropriate to be used in clinic. Further targeting of HIV-1
inhibition by La(W) is under progress.
Copyright © 2006 Ilia Manolov et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
The need for new HIV inhibitors especially directed to so
far unexploited primary targets (integrase, RNase H, viral
assembly, etc) is considered to be promising for the devel-
opment of anti-HIV drugs. Coumarins and bicoumarins are
widely spread in nature [1, 2]. Their biological properties are
also well known and include anticoagulant, antiproliferative,
antimicrobial,spasmolytic,antitumor,antioxidant,andanti-
HIV eﬀect reported recently [3].
A large number of structurally novel coumarin deriva-
tives have been reported to demonstrate anti-HIV activity in
vitro and in vivo [4, 5]. Plant-derived and semisynthetic cal-
anolide compound exhibited in vitro activity against HIV-1
and human cytomegalovirus [6]a n dh a sb e e np r o v e nt ob ea
naturallyoccurringnonnucleosidereversetranscriptase(RT)
inhibitor [1]. Tipravirin, a novel HIV-1 protease inhibitor,
has been developed from a nonpeptidic coumarin template
[7]. Mazumder et al [8], investigating the eﬀect of several
HIV-1 protease inhibitors containing 4-hydroxycoumarin
(4-hc) residues, have found antiviral, antiprotease and anti-
integrase activities. It has been reported that coumarin and a
number of its 4-hc and 7-hc derivatives, including warfarin
(W), display cytotoxic eﬀect against tumour cell growth and
metastases dissemination [9, 10].
Unfortunately, little is known about the complexing abil-
ity of lanthanides—cerium Ce(III), lanthanum La(III), and
neodymium Nd(III)—with coumarins. Earlier it has been
shown that interesting metalorganic compounds of men-
diaxon, warfarin, coumachlor, and niﬀcoumar with lan-
thanides displayed antitumor activity against P3HR1, K-562,
and THP-1 cell lines [11–15]. The complexes had stronger
cell proliferation-inhibiting eﬀects compared to the inor-
ganic salts. One could expect that lanthanide complexes with
selected active coumarin ligands should retain or even im-
prove their biological activity similarly to other lanthanide
complexes with hc derivatives.
Here we present the coordination ability of 4-hydroxy-3-
(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one (warfarin)
(W)a n d3 , 3  -benzylidenebis[4-hydroxycoumarin] (1)i n2 Bioinorganic Chemistry and Applications
complexation reaction with Ce, La, and Nd. An increased
anti-HIV activity of La(W)( I C 5 0 =21.4μM) as compared to
(W) (7.1% inhibition at maximal nontoxic concentration—
MNC)hasbeendemonstrated.Furtherstudyhasshownlim-
ited anti-HIV potency of Nd(W), Ce(1), and Nd(1), so none
of the complexes seems appropriate to enter clinical trials.
Studies indicated clearly that HIV-1 RT and protease for all
complexes were not the targets of antiviral activity.
EXPERIMENTAL
Sourcesubstancesforsynthesis
Merck products p.a. Ce(NO3)3 ·6H2O, La(NO3)3 ·6H2O,
Nd(NO3)3·6H2O. 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-
1-benzopyran-2-one (W)a n d3 , 3  -benzylidenebis[4-hydro-
xycoumarin] (C25H16O6) (1) were synthesized by us and
were used to prepare the solutions.
Ln(III) complexes of (W) were synthesized using warfarin
sodium salt. The synthesis and analysis of the complexes of
(W) were described previously [11].
The complexes of lanthanides(III) with (1) were synthe-
sized by reaction of lanthanide(III) salts and the ligand in
amountsequaltometal:ligandmolarratioof1 : 2.Thecom-
plexes were prepared by adding an aqueous solution of lan-
thanide(III) salts to an aqueous solution of the ligand sub-
sequently raising the pH of the mixture gradually to ca 5.0
by adding dilute solution of sodium hydroxide. The reaction
mixture was stirred with an electromagnetic stirrer at 25◦C
for an hour. The precipitate formed at the moment of solu-
tionmixingwasﬁltered,washedseveraltimeswithwater,and
dried in a dessicator to constant weight. The complexes were
insoluble in water, slightly soluble in methanol and ethanol,
and well soluble in DMSO.
Analyticalandspectroscopicmeasurements
The elemental analyses for C, H, Ln, and H2O were per-
formed according to standard microanalytical procedures.
T h eI Rs p e c t r a( N u j o la n dK B r )w e r er e c o r d e do nI R -
spectrometer FTIR-8101M Shimadzu (3800–400cm−1)a n d
on IR-spectrometer Perkin-Elmer GX Auto image system
(700–200cm−1). The 1H NMR spectra were recorded at
roomtemperatureonBruckerWP250(250MHz)spectrom-
eter in DMSO-d6.T h e13C NMR spectra were recorded at
ambient temperature on Brucker 250 WM (62.9MHz)spec-
trometer in DMSO-d6. Chemical shifts are given in ppm
downﬁeld from TMS. The mass spectra were recorded on a
Jeol JMS D 300 double-focusing mass spectrometer coupled
to a JMA 2000 data system. The compounds were introduced
by direct inlet probe, heated from 50◦C to 400◦Ca tar a t eo f
100◦C/min. The ionization current was 300mA, the acceler-
ating voltage 3kV, and the chamber temperature 150◦C.
Cells,viruses,andassays
Celllines
The following cell lines were used: H9/HTLV III B—
chronically infected with HIV-1LAI cells, kindly provided
by Professor R. Gallo, and MT-2 uninfected human lym-
phoblastoid cells, HTLV-I transformed. The cells were main-
tained in RPMI 1640 plus 10% FCS.
HIV-1source
As a source of HIV-1, the supernatant of H9/HTLV III B
cell line was used. The supernatants were collected and cen-
trifuged to remove the cells, and virus stocks were prepared
with known p24 antigen content, RT activity and infectiv-
ity. MT-2 cells were infected with HIV-1 (multiplicity of in-
fection ≥ 1) in suspension (37◦C/5% CO2) and then grown
parallely with uninfected ones for 72 hours.
Cytotoxicityandanti-HIVassays
The following parameters were studied: cytotoxic concen--
tration 50—CC50 (concentration preventing death of 50%
of MT-2 cells), maximal nontoxic concentration—MNC
(the highest concentration causing no cytotoxicity), and in-
hibitoryconcentration50–IC50(concentrationinhibitingby
50% the viral replication). CC50 and MNC were detected
by neutral red uptake assay [16]. IC50 was studied on MT-
2 cells by microtiter infection assay using neutral red uptake
[16].Brieﬂy,theexperimentalprocedureunderconditionsof
acute infection was performed in 96-well microplates in the
following sequence:
(i) 100μLM T - 2c e l l s( 4 – 5×104 cells);
(ii) 50μL HIV-1 (undiluted or in the appropriate dilution
to obtain multiplicity of infection ≥ 1); contact (2
h o u r sa t3 7 ◦C/5% CO2); when CC50 and MNC were
detected, growth medium instead of virus has been
added;
(iii) 50μL sample of substance tested starting from 4×
MNC (because this volume is 1/4 of the whole vol-
ume in the well) and 2- or 10-fold dilutions in growth
medium.
The cells were incubated for 72 hours and then 100μL
of them were removed to another 96-well plate previously
treatedforanhourwith50μg/mLpoly-L-lysine(PLL)invol-
ume 100μL. A solution of 100μL per well of neutral red in
growth medium (0.016%) was added and the cells were in-
cubatedfor2hoursat37◦C/5%CO2.N eutralr eddy ewasex-
tracted by acidiﬁed alcohol (50% ethanol in 1% acetic acid)
and measured colorimetrically at 540nm. Each plate con-
tained 8 cell control wells (no virus, no substance) for all
kinds of experiments. When IC50 was detected, a row of 8
viral controls (plus virus, no substance) and rows of 8 exper-
imentalwells(plusvirus,diﬀerentdilutionsofthesubstance)
were performed. The values of optical density at 540nm
(OD540) were averaged for each row and the mean values
of experimental and control rows were compared. As far as
the ligands and their complexes were DMSO soluble, the ap-
propriate controls of DMSO and DMSO + HIV-1 in growth
medium were always considered.
The eﬀect of the compounds was also studied under con-
ditions of chronic infection using productively HIV-infectedIlia Manolov et al 3
cells (H9/HTLV III B). The production of infectious viri-
ons was measured again using the cytopathic eﬀect of super-
natants on MT-2 cells as described above.
DetectionofRTactivity
Endogenous RT activity of supernatants of HIV-1 infected
MT-2cellstreated/untreatedwithcomplexesandligandswas
tested by HS-Lenti Kit-RT assay (Cavidi, Sweden). The kit
contained recombinant RT (rRT) as a standard which made
possible quantitation of the RT in the sample. The method is
nonradioactiveandcolorimetricallydetectsRTactivityprod-
uct (DNA) at 405nm (OD405) [3].
RTprocessivitybypolymerasechainreactions
The idea was to demonstrate how far the proviral DNA syn-
thesis has progressed and whether mRNA splicing has oc-
curred within HIV-infected cells. (PCRs) were performed
using primers M661 and M667 detecting 200bp prod-
uct considered expressive for double-stranded (ds) provi-
ral DNA [17]. DNA for PCR was extracted from MT-
2 (negative control), HIV-1 infected MT-2 untreated cells
(positive control)/cells treated with IC50 or MNC (when
IC50 has not been reached) and on 4 and 24 hours af-
ter HIV-1 infection. The cells were collected in lysis buﬀer
(pH = 8.3, TRIS-HCl—10mM, KCl—50mM, MgCl2—
2.5mM, NP40—0.5%, and between 0.5% and 20% [17].
Nucleol-izing buﬀer (500μL) containing 30μL proteinase K
and25μL10%SDSwasaddedtothecelllysate.DNAwasex-
tracted by phenol-chloroform-isoamyl alcohol method. The
detection of ampliﬁed product was done after 35 cycles in
PCR machine and then visualized in 1.5% agarose gel.
RESULTS AND DISCUSSION
CharacterizationofLn(III)complexesof(W)
The compositions of the complexes of (W)w e r ec o n ﬁ r m e d
by elemental analysis, DTA and TGA, and mass-spectral
analysis. The binding mode of (W) was further elucidated by
IR and 1H NMR spectra of the complexes as compared with
this of the free ligand. Some of these data were presented by
us previously [11].
CharacterizationofLn(III)complexesof(1)
The elemental analysis data of the Ln(III) complexes
obtained are in agreement with the formula Ln(L)(OH)·
nH2O, where L = C25H14O6
2−. The results of the elemen-
tal analyses were within ±0.4% of the theoretical values. The
suggested formula was further conﬁrmed by mass-spectral
fragmentation analysis. As seen in Table 1, the ﬁrst peak in
the Ln(III) complexes spectra (although with low intensity)
corresponds to the mass weight of the complex formation
and the second one to that of the ligand. The results thus ob-
tained are in agreement with metal:ligand ratio, 1 : 1.
Table 1: Data of the mass spectra of the complexes of (1).
Ligand/complexes M/z (%)
H2L=C25H16O6
412 8
249 100
221 17
162 20
120 37
Ce(L)(OH) ·2H2O
586 8
410 35
305 98
176 100
La(L)(OH) ·H2O
586 8
410 35
305 100
176 100
Nd(L)(OH) ·H2O
589 2
410 1
307 68
176 100
The binding mode of (1) to Ln(III) was further eluci-
dated by analysis of the IR spectra of (1) and the complex
formation. A broadband characteristic for ν(O−H) of coor-
dinated water was observed in the spectra of the complexes
in the range of 3500–3450cm−1. The most notable change
in the ligand spectral features when coordinated to Ln(III) is
the observed C=O red shift. The ν(C=O) band at 1660cm−1
in the ligand spectrum exhibited a red shift of 40cm−1 in
the spectra of the complexes. This ﬁnding may be taken as
evidence for participation of the C=O group in coordina-
tion to the metal ion. Further, a comparison between the
ligand and complex IR spectra revealed that the absorption
bands associated with the stretching ν(O−H) of the phenolic
groups (observed at 3074cm−1 and 3032cm−1 inthe freelig-
and) disappeared in the Ln(III) complex spectra, indicating
a loss of phenolic protons on complexation and thus form-
ing a metal-oxygen bonds. The δ(COH) IP modes, which
appeared at 1345cm−1 and 1336cm−1 in the spectrum of
the ligand, were not observed in the spectra of the com-
plexes with Ln(III) and thus supported the suggestion that
the ligand coordinates to the metal through its deprotonated
form, L2−. The Ln(III) complex spectra showed new bands,
in comparison with that of the free ligand, at 570cm−1 and
410cm−1, and they were assigned to metal-oxygen stretching
vibrations, in agreement with literature.
The Ln(III) complexes and (1) were further studied by
their 1Ha n d13C NMR spectra. The changes of chemical
shiftsofthe 1HNMRspectrawereobservedinthecomplexes
(Table 2) and they were attributed to coordination of the lig-
and to Ln(III). The chemical shifts of the protons vary in the
lanthanidecomplexes,becauseoftheshiftpropertiesofthese
metals.
Due to electron transfer from the hydroxyl and carbonyl
oxygen atoms to Ln(III), chemical shifts to lower ppm were
observed for the neighboring C-4 and C-2 carbon atoms of4 Bioinorganic Chemistry and Applications
Table 2: 1H NMR spectra of the complexes of (1).
Compound H5−H8
a δ (ppm) H9
a H2 −H6 a
H2L=C25H16O6 7.11–7.39 6.37 7.56–7.92
Ce(L)(OH) ·2H2O7 .05–7.24 6.25 7.45–8.18
La(L)(OH) ·H2O6 .98–7.26 6.27 7.37–7.83
Nd(L)(OH) ·H2O7 .47–7.60 6.64 7.88–8.16
1 
2 
3 
4 
5 
6 
OH
CH
OH
OO O O 2
3
4 5
6
7
8
9
2
3 4a
5
6
7
8a
8
thecomplexesandtheyconﬁrmedtheexpectedcoordination
of the ligand through both deprotonated hydroxyl and car-
bonyl oxygen atoms (Table 3). The other carbon atoms were
only slightly aﬀected from the coordination of the metal. On
the basis of the results thus obtained, it was suggested that
the ligand acts as a tetradentate one in the Ln(III) complex
formation.
Cytotoxicityandanti-HIVassays
In Table 4, the cytotoxicity (expressed as CC50) and MNCs
of both ligands and their lanthanide complexes are shown.
As seen, the Nd complex of (1) demonstrated at least 5 times
lower cytotoxicity compared to the other lanthanides and
the ligand (1) itself. MNCs of the ligands diﬀered in be-
tween the complexes but were maximally nontoxic at 10–50
times higher concentrations for Nd(1)a n dC e ( 1)c o m p a r e d
toLa(1)andtheligand(1).Theligand(W)anditscomplexes
demonstrated both equal cytotoxicity and equal MNCs. As
far as intensive research is often being done to reduce the
toxicity of a compound, we demonstrate here that the com-
plexation with rare earth metals possibly leads to increase of
MNCs of some derivatives.
Dose-eﬀect dependence of ligands (1)a n d( W) and their
lanthanide complexes in HIV-1 infected MT-2 cells accord-
ing to microtiter infection assay [16] are listed in Table 5.
The results display the eﬀect on HIV replication of all lig-
ands/compounds in microtiter infection assay, starting from
MNC. As seen, the inhibitory eﬀects in MT-2/HIV-1 system
at or under the MNC values are very low for all but one of
the compounds under study—La(W)—58.4%. It is the only
derivative where IC50 could be reached—21.4μM. All other
compounds exhibit low antiviral potency according to this
assay.
Looking for the target of antiviral activity especially of
La(W)a sw e l la so f( W)a n dN d ( W), Ce(1), and Nd(1),
1 2 3 4 5 6 7 8 9 10
11 12 13 14 15 16 17 18 19 20
Figure 1: PCR representing HIV ds DNA synthesis after treatment
with ligands (1) and (W) and the complexes with anti-HIV activity
in microtiter infection assay (see Table 6). 35 PCR cycles. Ampliﬁ-
cation conditions: 93◦C3 0s ,5 7 ◦C9 0s ,7 2 ◦C 30s. 1.5% agarose gel.
we detected the endogenous RT activity in the supernatants
of HIV-1/MT-2 infected cells and compared it to the re-
sults from microtiter infection assay at similar conditions—
treatment for 72h with MNC. The results are demonstrated
in Table 6. Data indicate a discrepancy in anti-HIV eﬀect
measured by microtiter infection assay and endogenous RT
assay.Thislackofcorrespondenceisespeciallywellexpressed
fortheonlyactivecompound—La(W).Theresultsshowthat
the demonstrated anti-HIV activity cannot be explained by
inhibition of RT activity—that is, RT is not the target of anti-
HIV action. Therefore, another target to explain the eﬀect of
La(W) on HIV replication should be looked for.
Additional evidence that RT processivity has not been in-
ﬂuenced by (1)a n d( W) and their complexes having shown
some anti-HIV eﬀect were provided by PCR. Figure 1 shows
that HIV double-stranded (ds) proviral DNA synthesis was
not impaired by the complexes. One can see that 4h af-
ter treatment of HIV-infected MT-2 cells ds proviral DNA
was already observed in both treated (lanes 4, 5, 6, 7, 8, 9)
and untreated HIV-infected cells (lane 2), while MT-2 un-
infected cells displayed no ds DNA (lane 10). The same re-
sults but with more intense signal were registered 24h af-
ter treatment of HIV-infected MT-2 cells with (1)a n d( W)
compounds (lanes 14, 15, 16, 17, 18, 19). Therefore, the re-
sults conﬁrm that neither the ligands nor their rare metal
ions complexes have an inﬂuence on the reverse transcrip-
tion. So, once again, the discrepancy in anti-HIV activity
measured by microtiter infection assay and endogenous RT
detection is clearly demonstrated. The conclusion is that the
active La(W) and the other less potent anti-HIV agents have
no impact on the early steps of HIV replication.
To address further the target of HIV inhibition especially
by La(W), a study of this complex for eﬀect on late stages
of HIV-1 life cycle (protease, budding, assembly) was carried
out. To do this, we treated H9/HTLV III B cells—chronically
producing HIV-1—with La(W) at 3 concentrations, starting
from MNC. Also, 10× dilution of Indinavir was used as a
referenceforantiproteaseeﬀect.Table 7 representstheresults
for the eﬀect of La(W) in 3 concentrations on late stages of
HIV replication.Ilia Manolov et al 5
Table 3: 13C NMR spectra of the complexes of (1).
Atom δ (ppm)
H2L Ce(L)(OH) ·2H2O La(L)(OH) ·H2O Nd(L)(OH) ·H2O
C-2 165.3 167.8 164.6 167.7
C-4 164.9 164.7 152.7 164.6
C-8a 152.2 152.5 152.5 152.5
C-1  139.9 142.3 142.4 142.3
C-7 131.9 130.9 130.9 130.9
C-3  128.1 127.7 127.7 127.6
C-5  128.1 127.7 127.7 127.6
C-4  126.7 126.6 126.6 126.6
C-6  125.6 124.8 124.8 124.8
C-2  125.6 124.8 124.8 124.8
C-5 123.9 124.1 124.1 124.1
C-6 123.8 122.9 122.9 122.9
C-4a 117.9 119.9 119.9 119.9
C-8 115.9 115.4 115.4 115.4
C-3 104.1 103.4 103.4 103.4
C-9 35.93 6 .53 7 .53 6 .5
Table 4: Cytotoxicity as CC50 and MNCs of (1) and (W) and their
Ce, La, and Nd complexes studied by neutral red uptake assay [16].
Ligand
Ligand Ce La Nd
only complex complex complex
CC50 MNC CC50 MNC CC50 MNC CC50 MNC
μM μM μM μM μM μM μM μM
(1) 25 0,25 25 12,5 25 0,25 125 2.5
(W) 250 25 250 25 250 25 250 25
As seen, H9/HTLV III B cells produced almost equiva-
lent RT activity when treated with La(W)i n3c o n c e n t r a -
tions. Additionally, the number of infectious virions as mea-
sured by endpoint dilution analysis on MT-2 cells was equiv-
alent(onlyOD540valuesforundilutedsamplesareshown—
Table 7, column (c)). The data in Table 7 clearly demonstrate
no eﬀect of La(W) on late stages of HIV-1 replication in cell
culture. We especially accentuate that the late stages in this
study include atleastthreesteps—proteaseactivity, budding,
and assembly of HIV-1.
The fact that no eﬀect on RT and protease (expressing
early and late stages of HIV-1 replication) was registered;
one can suggest that RT and protease are not targets for the
antiviral activity of La(W). HIV-1 replication is too compli-
catedandanumberoftargetsandsteps(exceptthosestudied
here) should be taken into consideration (attachment, core-
ceptor binding, fusion, RNase H-activity, integration, inhibi-
tion of glycosylation or sialylation, etc). Although not espe-
cially being a subject of attachment studies, the results of RT
assays (Table 6) and RT processivity (Figure 1) clearly indi-
cate no eﬀect of the complexes on the earliest steps of repli-
cation. Research is now in progress to look for putative in-
hibitory eﬀect of La(W) ﬁrst on integration and then further
to specify the mechanism of its action.
Table 5: Dose-eﬀect dependence of ligands (1) and (W) and their
lanthanide complexes in HIV-1LAI infected MT-2 cells (72h in-
cubation) according to microtiter infection assay [16]. The con-
centrations tested start with MNC for each ligand/compound (see
Table 4).
Ligand/ Concentration Inhibition
compound (μM) (%)
(W) 25 7,1
2.5 0
Ce(W) 25 0
La(W)
25 58,4
2.5 2,0
0,25 0
Nd(W) 25 6,9
2.5 0
(1) 0,25 0
Ce(1)
12,5 11,5
2.5 8,7
0,25 0
La(1) 0,25 0
Nd(1) 2.5 10,4
0,25 0
Here we show for the ﬁrst time both complexation of
rare earth metal ions with selected coumarins and study of
their eﬀect on HIV replication in cell culture. Although the
complexes are of low potency against HIV-1 and should not
enter clinical trials, the experience with them shows once
more that the cytotoxicity could be reduced and the an-
tiviral eﬀect—highly expressed through complexation reac-
tions. Lack of protease and RT activity has been recently
reported for a number of HIV-1 integrase inhibitors [18]6 Bioinorganic Chemistry and Applications
Table 6:Comparisonofinhibition(%)ofHIV-1replicationinMT-
2 cells by microtiter infection assay and endogenous RT assay by
some lanthanide complexes of (1) and (W) at MNC (72h incuba-
tion).
Complex/ MNC HIV inhibition (%) HIV inhibition (%)
ligand (μM) Microtiter Endogenous
infection assay∗ RT activity∗
Ce(1)1 2 .51 2 .2 ∼ 1
Nd(1)2 .51 0 .4 ∼ 1
La(W)2 5 5 8 .4 ∼ 1
Nd(W)2 5 6 .9 ∼ 1
(W)2 5 7 .1 ∼ 1
∗Data averaged after at least 3 experiments.
Table 7: Data obtained after treatment of H9/HTLV III B cells with
diﬀerent concentrations of La(W) to target late stages of HIV-1
replication (protease, budding, assembly).
Compound Cells
RT Microtiter
Concentration activity of infection
( μM) SNs1 assay2
OD405 OD540
(a) (b) (c)
H9/HTLV III B 25 2.980 1.530
treated with 2.5 2.987 1.525
La(W) 0.25 2.926 1.520
SN from — 0.244 1.501
MT-2 cells
SN from — 2.859 0.434
MT-2/HIV-1
SN from
— 2.872 1.539 H9/HTLV
III B
H9/HTLV III B
50 0.903 0.375 treated
with
Indinavir
5 1.154 0.520
0.5 1.400 0.633
0.05 1.454 0.739
1SN—supernatant.
2H9/HTLV III B were treated for 72 hours with La(W)i n
designated concentrations (a) and RT activity in supernatants was
measured (b). Thereafter, MT-2 cells were infected with 50μLo f
undiluted supernatants of H9/HTLV III B cells from (b) and
microtiter infection assay was carried out as described (c)—see
Experimental.
and on the contrary, antiviral agents inhibiting both inte-
grase and protease have also been published [8]. The unique
and variable activities of plant-derived and semisynthetic
c o u m a r i n s ,a sw e l la sn o v e la p p r o a c h e sf o rs y n t h e s i so fp o -
tent and less toxic derivatives could facilitate generation of
new lead compounds for chemotherapeutic intervention.
The lanthanide complexes with selected coumarins could of-
fer such an opportunity.
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